Alto Neuroscience (NYSE:ANRO) Given New $10.00 Price Target at Robert W. Baird

Alto Neuroscience (NYSE:ANRO) had its price target cut by Robert W. Baird from $32.00 to $10.00 in a research note released on Wednesday morning, Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other equities research analysts have also weighed in on the stock. Wedbush restated an “outperform” rating and issued a $29.00 price objective on shares of Alto Neuroscience in a report on Tuesday, September 10th. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Finally, Rodman & Renshaw cut Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $24.40.

Alto Neuroscience Trading Down 70.0 %

Shares of ANRO stock opened at $4.36 on Wednesday. Alto Neuroscience has a fifty-two week low of $4.26 and a fifty-two week high of $24.00. The company has a debt-to-equity ratio of 0.04, a quick ratio of 19.85 and a current ratio of 19.85. The company has a 50 day moving average price of $12.22 and a 200 day moving average price of $12.48.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.07. Sell-side analysts forecast that Alto Neuroscience will post -2.63 earnings per share for the current year.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors and hedge funds have recently bought and sold shares of ANRO. Federated Hermes Inc. grew its holdings in shares of Alto Neuroscience by 33.3% during the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock worth $128,000 after purchasing an additional 3,000 shares during the last quarter. Bowie Capital Management LLC acquired a new position in Alto Neuroscience during the second quarter worth approximately $462,000. TD Asset Management Inc purchased a new stake in Alto Neuroscience in the second quarter valued at approximately $928,000. Rhumbline Advisers acquired a new stake in shares of Alto Neuroscience in the second quarter valued at approximately $113,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Alto Neuroscience during the second quarter worth approximately $252,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.